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Hypoxic-ischemic encephalopathy (HIE) is a clinical condition in the neonate, resulting from
oxygen deprivation around the time of birth. HIE affects 1–5/1000 live births worldwide
and is associated with the development of neurological deﬁcits, including cerebral palsy,
epilepsy, and cognitive disabilities. Even though the brain is considered as an immune-
privileged site, it has innate and adaptive immune response and can produce complement
(C) components and antimicrobial peptides (AMPs). Dysregulation of cerebral expres-
sion of AMPs and C can exacerbate or ameliorate the inﬂammatory response within
the brain. Brain ischemia triggers a prolonged inﬂammatory response affecting the pro-
gression of injury and secondary energy failure and involves both innate and adaptive
immune systems, including immune-competent and non-competent cells. Following injury
to the central nervous system (CNS), including neonatal hypoxia-ischemia (HI), resident
microglia, and astroglia are the main cells providing immune defense to the brain in a
stimulus-dependent manner. They can express and secrete pro-inﬂammatory cytokines
and therefore trigger prolonged inﬂammation, resulting in neurodegeneration. Microglial
cellsexpressandreleaseawiderangeofinﬂammation-associatedmoleculesincludingsev-
eral components of the complement system. Complement activation following neonatal HI
injury has been reported to contribute to neurodegeneration. Astrocytes can signiﬁcantly
affect the immune response of the CNS under pathological conditions through produc-
tion and release of pro-inﬂammatory cytokines and immunomodulatory AMPs. Astrocytes
express b-defensins, which can chemoattract and promote maturation of dendritic cells
(DC), and can also limit inﬂammation by controlling the viability of these same DC. This
review will focus on the balance of complement components and AMPs within the CNS
following neonatal HI injury and the effect of that balance on the subsequent brain damage.
Keywords:antimicrobial peptides,complement,neonatal hypoxia-ischemia,microglia,astrocyte,hypoxic-ischemic
encephalopathy
INTRODUCTION
Neonatal brain injury resulting from oxygen deprivation around
the time of birth affects 1–3/1000 live term births in high-income
countries with rates 5–10 times higher in low-resource setting.
About 40% of the affected infants die in the neonatal period
and additional 30% sustain lifelong neurological deﬁcits, includ-
ing cerebral palsy,epilepsy,and cognitive disabilities (1). Neonatal
hypoxia-ischemia induces a robust inﬂammatory response in the
immature brain, which is considered to play an important role
in the development of brain damage and subsequent hypoxic-
ischemic encephalopathy (HIE). Initial inﬂammation involves
activation and recruitment of various immune cells into the
injured brain. The initial pro-inﬂammatory response is followed
by hypoxic-ischemic (HI) secondary energy failure that may last
for days, followed by a switch to anti-inﬂammatory response
and resolution. However, the exact mechanisms involved in the
immune response following HIE still remain unknown. Several
mediators of the inﬂammatory cascade include components of
both innate and adaptive immune systems, such as cytokines,
chemokines,adhesionmolecules,aswellasantimicrobialpeptides
(AMPs) and complement (C).
NEONATAL HI
Despite the neonatal period only constituting the ﬁrst 28days
of life, it accounts for 38% of death in children younger than
5years of age. Direct causes leading to neonatal death include
infection (36%), prematurity (28%), and birth asphyxia (23%).
The latter two, combined with congenital defects (7%) account
for the majority of deaths occurring within the ﬁrst week of life
(2). This morbidity is generally a result of multiple organ dys-
functions(3)orterminationof care.Epidemiologicalstudieshave
shown that asphyxia is not the most common cause for develop-
mental disorders; however, it poses important clinical problems,
as infants who survive an asphyxia episode around the time of
birth are at high risk of developing lifelong devastating impair-
ments. Neonatal HIE and the ensuing clinical manifestation cause
signiﬁcantglobalpublichealthburden(4),withinfantsufferersat
risk of subsequently developing cerebral palsy and/or other neu-
rologicaldysfunctionssuchascognitiveimpairment,epilepsy,and
autism (4–6).
The pathophysiology of brain injury resulting from birth
asphyxia includes evidence of fetal stress in the hours leading to
birth, associated with depression at birth, need for resuscitation,
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Table 1 | Mechanisms of HI injury.
Primary energy failure
Decline in cerebral blood ﬂow, O2 substrates, and high-energy phosphate
compounds
Initiation of neurotoxic cascade
Reduction of membrane homeostasis leading to calcium inﬂux,
mitochondrial dysfunction, brain acidosis, apoptosis, and necrosis
Latent phase
Normalization of oxidative metabolism
Secondary energy failure
Continuation of neurotoxic cascade
Inﬂammatory response
Caspase activation
Decrease in levels of protein synthesis and growth factors
Continuation of apoptosis and necrosis
evidence of metabolic acidosis as well as clinical and imaging
signs of neurological anomalies (7). This phase is classiﬁed as
primary energy failure, where reduction in cerebral blood ﬂow
and oxygen substrates leads to depletion in adenosine triphos-
phate ATP and phosphocreatine production and a switch from
aerobic to anaerobic metabolism, causing accumulation of brain
lactate and tissue acidosis (Table 1). Additionally, excitotoxic and
oxidative cascades cause excessive stimulation of neurotransmit-
ter receptors and cell membrane ionic transport failure, resulting
in accumulation of intracellular calcium (8, 9), and successive
cell swelling, activation of neuronal nitric oxide, and subsequent
release of reactive oxygen species leading to mitochondria dys-
function, apoptosis, and programed cell death (10). As soon as
the energy supplies are exhausted, cell necrosis occurs (11). Fol-
lowing successful reperfusion and resuscitation, there is a nor-
malization of cellular metabolism and intracellular pH leading
to neurotransmitter reuptake (12). However, in cases where the
hypoxic-ischemic episode is severe or prolonged, these cascading
events lead to a secondary energy metabolism failure in the mito-
chondria and subsequent persistence of excitotoxicity, oxidative
stress, induction of inﬂammatory response, activation of caspase
enzymes, and further apoptotic and necrotic cell death (12, 13).
NEONATAL HI AND INFLAMMATION
For a long period of time, the central nervous system (CNS) has
been regarded as an immune-privileged site. The blood–brain
barrier (BBB), formed by the endothelial lining of the cerebral
capillaries, the arachnoid multi-layered epithelium, and the CSF-
secreting choroid plexus epithelium, in conjunction with neigh-
boring cell types such as astrocytes and pericytes, prevents inﬁl-
tration of circulating immune cells, including B- and T-cells, and
diminishes the inﬂux of neurotoxic and neuroexcitatory agents
from the blood ﬂow (14). However, the CNS has the capacity
to generate innate and adaptive immune response. In the CNS,
the immune roles of peripheral neutrophils, dendritic cells (DC),
macrophages, and natural killer cells are replaced by microglia,
astrocytes, and oligodendrocyte precursors (15).
HI brain injury induces a robust inﬂammatory response in the
immature brain (16). Furthermore, injury to neurons leads to a
rapid change in their gene expression with stimulation of astro-
cytes and microglial activation and aggregation for survival sup-
port(17).Neuroglialactivationisagradedresponseaccompanied
by secretion of pro-inﬂammatory cytokines, causing increased
production of nitric oxide, reactive oxygen species, activation of
the vascular endothelium,and recruitment of peripheral immune
cells into the injured brain (18).
CNS IMMUNE CELLS
Microglia
Microglia are considered as the resident macrophages of the CNS
and account for 10–20% of total glial population. Under normal
physiological conditions, microglia are present in a resting state
with highly ramiﬁed and motile processes. However, in the pres-
ence of environmental changes to the brain, microglia become
rapidly activated, undergoing morphological changes involving
retraction of processes and increase in cell body size. Depending
on the extent of damage, microglial cells will further activate,
becomephagocyticandmigratetothesiteofinjury(19).Microglia
playanimportantroleinHIE.Retrospectivepost-mortemclinical
studies have shown substantial microglial activation and inﬁl-
tration in the hippocampal dentate gyrus of HIE infants, which
was not observed in infants who had died from trauma or sep-
sis (20). Microglial contribution to secondary energy failure is
thought to occur via production of pro- and anti-inﬂammatory
cytokines such as interleukin (IL)-1b,IL-6,tumor necrosis factor-
alpha (TNF-a) (21, 22), as well as expression of toll like recep-
tors (TLRs) and antigen presentation (Figure 1). Microglial cells
are also able to release matrix metalloproteinases, thus lead-
ing to breakdown of the BBB, allowing inﬂux of leukocytes
into the no longer immune-privileged CNS, thus exacerbating
inﬂammation and subsequent brain damage (23). However,there
are contradicting experimental mouse data on whether inhibi-
tion of microglial activation following neonatal HI is beneﬁcial
(24, 25). The microglial innate immune response is character-
ized by classical or M1 activation with subsequent production
of associated pro-inﬂammatory molecules, followed by resolu-
tion and a switch to alternative or M2 phenotype leading to
anti-inﬂammatory signaling and clearance of reactive species and
wound healing (26).
Astrocytes
Astrocytes are the most abundant cell type in the CNS. They
are essential supporters of brain homeostasis and neuronal func-
tionandalsoregulatesynaptogenesis(27).However,post-mortem
clinical studies have demonstrated a prevalence of astrogliosis
of 15–40% within the white matter of HI infants (28). Under
HI conditions, pro-inﬂammatory mediators, cytokines, and reac-
tive species produced by damaged neurons and oligodendrocytes
can lead to astrogliosis. Activated astroglia, despite not being
considered as a traditional inﬂammatory cell, secrete inﬂamma-
tory cytokines such as IL-1, IL-6, interferon-g, and TNF-a (29).
Increased levels of these cytokines exacerbate nitric oxide toxicity,
and both apoptosis and necrosis,thus aggravating HI injury (30).
Astrocytes can also produce chemokines, which attract migra-
tion of immune cells into the CNS (31). Astrocytes have TLRs
and respond to TLR ligands. Following brain injury, astrocytes
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FIGURE 1 | Inﬂammatory response following HI injury. Neonatal asphyxia
leads to activation of microglia and astrocytes, which subsequently results in
increased synthesis and secretion of pro- and anti-inﬂammatory cytokines,
reactive oxygen species, and release of matrix metalloproteinases.This is
associated with BBB breakdown, as well as inﬂux of leukocyte and
lymphocyte immune cells into the injured brain.
also express major histocompatibility complex (MHC) and co-
stimulatorymolecules,developTh2immuneresponse,andinhibit
expression of IL-12 (27).
PERIPHERAL IMMUNE CELLS
Neutrophils
It is well established that HI brain injury is associated with inﬁl-
tration of inﬂammatory cells into the brain. Neutrophils are the
most abundant type of leukocytes and are an integral part of
the innate immune system. Although in adult rodent models of
ischemic insult, neutrophils are known to accumulate within the
brain as early as 4–6h post injury, and lasting up to 48h (32,
33), this does not appear to be the case in neonatal HI injury,
where inﬁltration of neutrophils into the injured brain is less
marked, with a lesser number present at 42h post-insult. How-
ever, this same study demonstrated that neutropenic P7 rats had
70% reduction in brain swelling at 42h post-HI when compared
to littermate controls (34). Therefore, despite the suggestion that
neutrophils do not accumulate in the immature brain following
HI,they still play a relevant role in exacerbation of neonatal brain
damage.
Lymphocytes
Lymphocytes are granulocyte blood cells crucial in the immune
response, and contribute to either adaptive (B- and T-cells) or to
innate(NK-cells)immunity.Inexperimentaladultrodentstudies,
lymphocytes are shown to inﬁltrate the CNS within a few hours
after cerebral ischemia,and to remain within the brain for several
days(35,36).AnadultmousestudyusingRAG1 /  micedeﬁcient
in both B- and T-cells has shown a substantial reduction in cere-
bralinfarctioninthemutantsfollowingcerebralarterialocclusion.
Furthermore, the same study demonstrated that mature B-cell
negative animals did not show an altered response to ischemic
injury (37). Interestingly, in the neonatal mouse model of middle
cerebral arterial occlusion (MCAO), T-cell inﬁltration appears to
occur only after 24h post-insult and persists for up to 96 after
injury(38).Thiscouldbeduetoimmaturityof lymphoidprogen-
itorsatthisstageof braindevelopmental.Aclinicalstudyassessing
peripheral blood if infants with HIE showed that blood mononu-
clear cells are still relatively undifferentiated in newborns, with
reduced expression of surface markers (39). However, in chronic
inﬂammatoryresponsetoHIinjury,CD4lymphocytesarepresent
within the infarcted brain regions 7days after injury, and persist
within the area of damage for a long period of time (40).
Dendritic cells
Dendritic cells are antigen-presenting cells recognized by T-cells
and acting as messengers between adaptive and innate immune
system. Initial IL-1b and TNF-a response, as well as TLR acti-
vation cause translocation of NF-kB inﬂammation transcription
factorintothenucleusof preferentiallyDC,andalsomacrophages
and endothelial cells, inducing transcription of pentraxin-related
protein (PTX3), a soluble pattern recognition receptor from the
lectin family (41, 42). Pentraxin not only assists the recogni-
tion of microbes and ampliﬁcation of innate immunity but is
also involved in the clearing of self-components and decreased
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DC recognition of apoptotic cells (43). A study looking at global
pattern of gene expression following neonatal HI has shown acti-
vation of PTX3, suggesting a possible role for DC involvement in
the subsequent immuno-inﬂammatory response (16).
INFLAMMATORY MEDIATORS
Cytokines
Bothpro-andanti-inﬂammatorycytokinesandtheirreceptorsare
present in the brain and cerebrospinal ﬂuid,and act as an integral
partof theCNSinﬂammatoryresponsetoadverse stimuli(44).In
fact, it is widely accepted that cytokines work as a ﬁnal common
pathway to injury from a number of varying insults, including
HI. The most widely study cytokines in ischemic models of brain
injury are IL-1, IL-6, IL-10, TNF-a, and transforming growth
factor-b (TGF-b). From these, IL-1, IL-6, and TNF-a appear to
exacerbate brain injury (45), whereas IL-10 and TGF-b may have
neuroprotectivefunctionfollowingischemicinjury(46).Theearly
response IL-1,IL-6,and TNF-a cytokines are believed to be inﬂu-
ential in the progression of injury in the immature brain via
stimulation of synthesis of other cytokines and adhesion mole-
cules, and prompting leukocyte inﬁltration, which in turn will
lead to further recruitment of immune cells, as well as induction
of neuronal injury mediators such as nitric oxide. This continual
and progressive stimulus has inﬂuencing modulatory effects on
glial gene expression and activation. Depending on the extent of
cytokine-mediatedcytotoxicinﬂammatorycellularactivation,cell
damage and subsequent death occurs (47, 48). Prospective clini-
cal studies have shown an association between high levels of IL-1,
IL-6, and TNF-a and infants who are deceased at 1year of age
or diagnosed with cerebral palsy (49). Subsequent clinical studies
have also demonstrated a correlation between IL-1 CSF levels and
HIE (50). Serum IL-1b, IL-6, IL-8, and TNF-a have demonstra-
ble correlation with the MRS biomarker of anaerobic respiration
lactate/choline (51). Additionally, CSF IL-6 levels after neonatal
asphyxia are also associated with both early and late neurological
outcomes and severity in HIE (52).
Chemokines
Chemokines are chemotactic cytokines thought to act together
with different adhesion molecules such as selectins,integrins,and
immunoglobulins in order to control immune cell trafﬁcking.
These proteins play a detrimental role in various neurodegenera-
tion models, including HI, ischemic stroke, and excitotoxic brain
injury (53). A neonatal mouse study of HI injury has demon-
strated that mRNA expression of chemokines precedes inﬁltra-
tion of immune cells into the brain, thus proving its relevance
in the inﬂammatory response following insult to the immature
brain (31, 40).
Adhesion molecules
Adhesion molecules, including selectins, integrins, and
immunoglobulins, play an essential role in leukocyte inﬁltration
tothebrain.Initially,adhesionmoleculeshavelowafﬁnitybinding
consisting of rolling of cells, resulting then in high afﬁnity bind-
ing and ﬁrm adhesion (54). Targeting these molecules in stroke
experimental models has demonstrated their importance in brain
injury, as inhibition of leukocyte adhesion resulted in improved
neurological and histological outcome, whereas over-expression
increased tissue infarction (55–57). However,the role of adhesion
molecules in HIE still remains largely unknown.
ANTIMICROBIAL PEPTIDES
Antimicrobial peptides are a diverse group of cationic polypep-
tides containing less than 100 amino acid residues. AMPs were
discovered through studies of the insect antimicrobial defense
mechanismsandthepathwaysinvolvedinintracellularphagocyto-
sisofbacteriaindifferentmammalianspecies(58).Foralongtime,
AMPs were associated with antimicrobial and antifungal activities
through opsonization, agglutination, neutralization, or destruc-
tion of pathogens (59). Emerging evidence suggests chemotactic
andimmunomodulatorycharacteristicsofAMPsthroughchemo-
taxis, phagocytosis, cytokine production, production of reactive
oxygen species, and maturation of DC (59–61). Most AMPs have
a positive charge and are divided into several categories based on
primary structure and topologies (62), although the most well
studied AMPs are cathelicidins and defensins.
Defensins contain six conserved Cys residues forming three
disulﬁde bridges. Depending on the spacing between the Cys
residues and the topology of the disulﬁde bonds defensins are
classiﬁedina-,b-,or"-(61,62).Defensinsarepresentinmanyani-
malspeciesandtheirexpressionisassociatedwithcellsandtissues
involved in host defense against microbial infections (Table 2).
Depending on the cell type expressing them, defensins act either
intracellularlythroughoxygen-independentdestructionofphago-
cytosed microorganisms or are secreted in the extracellular milieu
where they directly attack the microbial membrane. Therefore,
defensins are either stored as granules of neutrophils and Paneth
cellsof thesmallintestineorsecretedbymonocytes,macrophages,
natural killer cells, keratinocytes, and epithelial cells (61).
a-defensins were ﬁrst characterized as antimicrobial proteins
puriﬁed from extracts of cytoplasmic granules of polymorphonu-
clear leukocytes (PMNs) (63). Human a-defensins are produced
by leukocytes, Paneth cells, and epithelial cells of the female uro-
genital tract. There are six a-defensins, called human neutrophil
peptide (HNP) 1–4 and human defensins 5–6 (64). In addi-
tion to their antimicrobial activity, some a-defensins (HNP-1)
possess also antiviral characteristics. HNP-1 inhibits HIV and
inﬂuenza virus replication, and inactivates herpes simplex virus,
cytomegalovirus, vesicular stomatitis virus, and adenovirus (61).
There are four b-defensins known as human beta defensins
(HBDs) 1–4 and possessing structural similarity to the a-
defensins. HBD-1 was ﬁrst isolated from human plasma and is
constitutively synthesized by epithelial cells of the urinary and
respiratorytracts(62),aswellaskeratinocytes(65).HBD-1expres-
sion can be up-regulated through treatment with lipopolysaccha-
ride (LPS),peptidoglycan,and interferon-g (62). HBD-2 was ﬁrst
puriﬁedfrompsoriaticscalesand itsexpressionoverlapswiththat
of HBD-1, but HBD-2 is also present in skin, pancreas, leuko-
cytes, and bone marrow. HBD-3 was identiﬁed simultaneously
in psoriatic scales and through bioinformatics, and apart from
epithelia is also expressed at lower levels in non-epithelial cells
of the heart, liver, fetal thymus, and placenta. HBD-4 was identi-
ﬁedbygenomics(66)anditsexpressionhasbeenassessedthrough
detectionofmRNAandconsideredtooccurprimarilyintestisand
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Table 2 | Cell sources and expression of defensins and cathelicidin.
Name Defensin type Cell source Tissue Production Activity
HNP 1–4 a PMNs Abundant Constitutive Antimicrobial
Inducible Antiviral
HBD 5–6 a Paneth cells Abundant Constitutive Antimicrobial
Epithelial cells Chemotactic for PMNs and
T-cells
HBD-1 b Epithelial cells Urinary and respiratory
tracts
Constitutive and inducible
(LPS, peptidoglycan,
interferon-g)
Antimicrobial
Keratinocytes Chemotactic for monocytes,
dendritic cells, and CD4T-cells
HBD 2–4 b Epithelial cells Psoriatic scales Inducible (IL -1,TNF-a, LPS) Antimicrobial
Keratinocytes
LL -37 Cathelicidin Epithelial cells, neutrophils,
T- and B-lymphocytes,
NK-cells, keratinocytes
Thymus, spleen, skin, liver,
bone marrow, stomach,
intestine and testis
Constitutive and inducible
(insulin-like growth factor
1,TNF-a, IL -1 a, IL -6)
Chemotactic for granulocytes
and CD4T-cells
HNP , human neutrophil peptide; HBD, human beta defensin; PMN, polymorphonuclear leukocytes.
epididymis (62). HBD2–4 are inducible and can be up-regulated
in response to pro-inﬂammatory stimuli such as IL-1, TNF-a,
and LPS. Multiple defensin genes have been discovered suggesting
more HBDs on peptide level (67).
The third family of defensins, the "-defensins, generate from
precursor peptides of a-defensins (68) and have been identiﬁed
in rhesus macaque monkey leukocytes. The "-defensins are not
expressed in humans due to mutations encoding premature stop
codons (69).
Cathelicidins are another major group of structurally and evo-
lutionary distinctive mammalian AMPs constitutively expressed
in thymus, spleen, skin, liver, bone marrow, stomach, intestine,
and testis, and therefore similar in abundance of expression to
the defensins (61, 66, 68). There is only one human catheli-
cidin gene encoding the amphipathic alpha-helical peptide LL-37
(64). Cathelicidins are constitutively expressed in epithelial cells,
neutrophils, T- and B-lymphocytes, NK-cells, and in mouse and
human mast cells, and their synthesis can be enhanced by LPS
and lipoteichoic acid (66, 70). Cathelicidins have direct antimi-
crobial effect on GramC and Gram  bacteria and their syn-
thesis in keratinocytes can be induced by Staphylococcus aureus.
Some cytokines (insulin-like growth factor 1, TNF-a, IL-1a, and
IL-6) can also induce the synthesis of LL-37 in keratinocytes
(61). There are other AMPs, i.e., lysozyme, azurocidin, and
bactericidal/permeability-increasing protein, which also possess
antimicrobial activities and enhance phagocytosis (64).
AlthoughAMPsaremostlyknownfortheiranti-bacterialprop-
erties, a great number of them also possess chemotactic features.
a-defensins are chemotactic for PMNs and T-cells, HBDs for
monocytes, DC, and CD4 T-cells, while LL-37 are chemotac-
tic for granulocytes, as well as CD4 T-cells. All this suggests an
essential role of AMPs as a link between innate and adaptive
immunity. Generally, AMPs have antimicrobial properties, but
are also an essential part of the inﬂammatory response (71), and
differentenvironmentalstimuliinvolvingmultiplesignalingpath-
ways promote their synthesis. Pro-inﬂammatory molecules (IL-1,
TNF-a, IL-6) and bacterial products augment the expression of
cathelicidins and defensins through activation of AP-1,JAK2,and
STAT3 signaling pathways (61). Altogether AMPs appear to be a
crucialcomponentoftheantimicrobialhostdefense,directlyinac-
tivating the pathogens and contributing to the immune response
associated with the pathogen removal.
COMPLEMENT
The complement system is a crucial component of innate immu-
nity and is responsible for the recognition and elimination of
pathogens. Its activation is associated with inﬂammatory media-
tion (72, 73) and induction of pro-inﬂammatory cytokines secre-
tion (72). Activation of the complement system also facilitates
clearanceof toxiccelldebris andapoptoticcells (74–76),as wellas
immune complexes (72, 76, 77).
The complement system plays an important role in various
inﬂammatory disorders. Its activation can signiﬁcantly contribute
to inﬂammation-mediated tissue damage following ischemic-
reperfusion injury (78), whereas complement deﬁciencies highly
favor the development of autoimmunity (79). The accumula-
tion or unsuccessful removal of cellular debris may contribute
to autoimmune disorders like systemic lupus erythematosus
(75), as well as various chronic inﬂammatory diseases like age-
related macular degeneration (76),rheumatoid arthritis (80),and
asthma (81).
The complement system consists of more than 30 soluble and
cell-associatedfactorsandcanbeactivatedthroughthreepathways
(classical, alternative, and lectin) (Figure 2). The components of
the complement system are synthesized to a great extent not only
by hepatocytes but also by tissue macrophages, blood monocytes,
andepithelialcellsof thegastrointestinalandgenitourinarytracts.
INNATE IMMUNITY OF THE BRAIN
Both AMPs and C components are important factors of the
innate immune system. Besides the fact that AMPs and C com-
ponents are mostly produced in the periphery and that the
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FIGURE 2 |Activation of the complement cascade. Activation of all three C
pathways generates homologous variants of C3-convertase cleaving C3 into
C3a and C3b, whereas C3a stimulates mast cell degranulation and has
chemotactic properties, and C3b acts as an opsonin and binds to the surface
of pathogens. Increasing C3b deposition leads to the formation of
C5-convertases cleaving C5 into the chemotactic C5a, and the fragment C5b,
which together with C6, C7 , C8, and the polymeric C9 forms the membrane
attack complex (MAC) leading to the formation of transmembrane channel
and osmotic lysis of the targeted pathogen.The classical pathway (CP) is
initiated by binding of the C1-complex, consisting of a C1q molecule and a
tetramer of 2 C1r and 2 C1s molecules, to antigen-bound IgM or IgG.The
C1-complex cleaves C2 and C4 into C2a and C2b, and C4a and C4b,
respectively.The C2a and C4b fragments form the CP C3-convertase.The
lectin pathway activation is due to binding of mannose-binding lectin (MBL)
and ﬁcolins (Ficolin-1, -2, and -3) to carbohydrate pattern on microorganisms
and dying cells, thus activating the MBL-associated serine proteases MASP-1
and MASP-2, which would in turn cleave C2 and C4.The alternative pathway
(AP) is continuously activated through spontaneous C3-hydrolysis, resulting in
formation of C3 convertases, which cleave C3 to a C3b-like C3, i.e., C3(H2O).
Complement regulators are typically present on host cells and absent on
pathogens, thus allowing C3(H2O) to bind factor B on the surface of the latter,
and form additional C3 convertases after activation by factor D. In the
presence of Factor D, C3(H2O)B is cleaved to Ba and Bb and forms
C3(H2O)Bb, which in turn cleaves C3 to C3a and C3b forming C3bBb, which is
stabilized by properdin. Properdin bound to microbial surfaces and apoptotic
and/or necrotic cells can recruit C3 and also activate the AP (82).The ﬁnal
C3bBbP complex enzymatically cleaves more C3 and ampliﬁes C activation.
The C3-convertase of the AP can bind another C3b fragment and the resulting
complex C3bBbP(C3b)n acts as a C5-convertase and triggers the formation of
MAC and pathogen elimination.
BBB permeability is not absolute, there is evidence suggest-
ing that both groups of proteins can be also produced in the
brain (15, 83, 84).
GLIAL CELLS IN INNATE IMMUNITY OF THE BRAIN
As previously mentioned,both microglia and astroglia are impor-
tant participants in the innate immune response of the brain and
both cell types can produce complement components and AMPs,
as well as cytokines (Table 3).
NEURONS IN INNATE IMMUNITY OF THE BRAIN
In the brain, immune function and modulatory activity are not
featuresattributedonlytoimmunecompetentcells,i.e.,microglia
and astrocytes, but also to non-immune cells. Neurons were
originally considered to be just effector cells of C activation
and neurodegeneration resulting from glial activation or cytokine
inﬂux through the BBB. However, neuronal expression of mRNA
for C1q, C2, C3, C4, C5, C6, C7, C8, and C9 has been observed in
post-mortem tissue from patients with Alzheimer’s disease (AD)
(15, 73). Neuronal expression of C1-inhibitor has also been reg-
istered in AD cerebral tissue, suggesting expression of C regulator
proteins and protection from full C activation associated with
membrane attack complex (MAC) formation and cell lysis. Clus-
terin, C3aR, Factor H, and S protein have also been detected in
neurons (73). Therefore,through its capacity of de novo synthesis
of Ccomponentsandregulators,theneuronalpopulationappears
to be an active player in the innate response of the CNS. So far,
there is no data suggesting neuronal AMP production.
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Table 3 | Expression ofTLRs, complement components, and antimicrobial peptides by microglia and astrocytes.
Cell type TLRs C components C regulators C receptors AMPs
Microglia TLR1,TLR3,TLR5-9 (158) C1q, C1r, C1s, C2, C3, C4 (73) C1-inhibitor (73) C1qR, CR3, C3aR,
CR4, C5aR (73)
HBD-1(109)
TLR2 (159) CD59, CR1 (15) LL -37 (91)
TLR4 (160)
Astrocytes TLR2 (161, 162) C1q, C1r, C1s, C2, C3, C4,
Factor B, Factor D, C5–C9 (73)
C1-inhibitor, Factor H, Factor I,
S protein, clusterin (73)
CD59, DAF , MCP , CR1 (15)
C1qR, CR2, C3aR,
C5aR (73)
HBD-1, HBD-2 (83),
LL -37 (91) TLR3 (163)
TLR4 (162, 164)
TLR5 (162, 164)
TLR9 (162, 164)
OLIGODENDROCYTES IN INNATE IMMUNITY OF THE BRAIN
Oligodendrocytes have also been shown to express C components
like C3, as well as C regulator proteins, in particular C1-inhibitor,
Factor H, S protein, and clusterin (73).
ENDOTHELIAL CELLS IN INNATE IMMUNITY OF THE BRAIN
Althoughthedatasuggestingexpressionof Ccomponentsbycere-
bralepitheliumisquitelimitedandpointsonlytowardproduction
of C3 (85) peripheral endothelium has been proven to synthesize
C1, Factor B, Factor H, and C5aR. Therefore, there is a possibility
that brain epithelium might be also producing these C compo-
nents. In respect to production of AMPs,synthesis and expression
of HBD-2mRNAandproteinhavebeenobservedinhumanbrain
capillary endothelial cells following exposure to Chlamydophila
pneumoniae (86). Overall, this data suggest a potential role of
brain epithelium in innate immune response and modulation.
COMPLEMENT COMPONENTS AND AMP EXPRESSION IN
THE BRAIN UNDER NORMAL CONDITIONS
Some immune proteins such as pro-inﬂammatory cytokines
(TNF-a, IL-6), MHC 1, and MHC receptors, apart from their
capacity to trigger and participate in an immune response, also
possess non-immune characteristics. Since C components are
shown to similarly demonstrate non-immune features, for exam-
ple, promote proliferation and regeneration in peripheral tissues
(76),itispossiblethattheyalsoexecuteanalogousfunctionsinthe
CNS. This hypothesis is supported by the observation that C3aR
can regulate in vitro differentiation and migration of neural prog-
enitor cells (87). In a study looking at the capacity of the classical
C pathway to mediate CNS synapse elimination, Stevens and col-
leagues observed association of C1q and C3 with remodeling of
synapticconnectionsinthevisualsystemof thedevelopingmouse
brain (88). Chu and colleagues observed enhanced synaptic con-
nectivity and epilepsy as a result of global deletion of C1q in mice
(89).C1qalsoaugmentsmicroglialclearanceofapoptoticneurons
and neuronal blebs and modulates the subsequent inﬂammatory
cytokine production (90).
In the CNS, only HBD-1 is proven to be constitutively
expressed. Hao and colleagues detected mRNA for HBD-1 in cul-
tured microglia, astrocytes, and meningeal ﬁbroblasts, but not in
neurons (83). Conversely, HBD-2 expression is not constitutive
but inducible and can be detected following exposure to LPS
and/or pro-inﬂammatory cytokines (LT-1b, TNF-a) (83). The
expression of cathelicidin LL-37 is also inducible and reported
in cerebrospinal ﬂuid and serum from patients with bacterial
meningitis (91).
COMPLEMENT COMPONENTS AND AMP EXPRESSION IN
THE BRAIN UNDER PATHOLOGICAL CONDITIONS
Most of our knowledge of the expression and function of C com-
ponentsandAMPsinthebrainisderivedfromstudiesof different
brain diseases. Both C and AMPs have been registered in bac-
terial meningitis and cerebral infections, in trauma, stroke, and
reperfusion injuries, as well as chronic conditions of brain injury
suchasAD,multiplesclerosis(MS),Parkinson’s,andHuntington’s
diseases.
COMPLEMENT AND AMPs IN ALZHEIMER’S DISEASE
Cribbs and colleagues observed up-regulation of innate immune
system pathways in post-mortem hippocampus from aged and
AD patients (92). The C system is associated with the inﬂamma-
tory response, occurring around the neuroﬁbrillary tangles and
amyloid-b (Ab) plaques in AD. Interestingly, different expression
ofCcomponentsisassociatedwiththedifferentneuropathological
progression stages of AD (15). In the early stages of AD,C1q,C4d,
and C3d are found, but MAC is absent, while in later stages the
levelsofC1q,C4d,andC3daremoreprominentandMACisregis-
tered in neuroﬁbrillary plaques and neurite tangles (93–98).Yaso-
jima and colleagues observed increased level of C1q in entorhinal
cortex,hippocampus,andmid-temporalgyrus,characterizedwith
high density of Ab-plaques and neurite tangles (99). Additionally,
TooyamaandcolleaguesdemonstratedthatC1qintheAbplaques
is endogenously produced in the AD brain (100) suggesting C1q
as an important mediator of AD inﬂammation. Genome wide
association studies have allowed considerable progress in under-
standing AD genetics, identifying loci, including CR1, which are
signiﬁcantly associated with AD susceptibility (101–103).
TheAb-plaquesandtheneuroﬁbrillarytanglesinADhavebeen
mostly associated with classical C pathway activation, whereas
alternative pathway (AP) has been documented only in the Ab-
plaques in human AD patients (104), and in murine AD models
(94). The participation of the AP in AD inﬂammation has been
conﬁrmed through AD mouse model using C1q /  mice, where
productsresultingfromC3cleavageandproperdinwereregistered
intheAb-plaques(94,105).Fonsecaandcolleaguesdemonstrated
that treatment with PMX205, a C5aR antagonist, signiﬁcantly
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reduces neuropathology in a mouse model of AD (106). How-
ever, the data retrieved from mouse models of AD and associated
with complement activation should be cautiously considered due
to the differences between the mouse models. Fonseca and col-
leaguesobservedamuchslowerprogressionof thediseasein3xTg
mice compared to other transgenic strains and suggested AP acti-
vation or a C3-independent cleavage of C5 accounting for the
detrimental outcome in these mice (107).
Conversely,the C system might as well play a protective role in
AD (93). Osaka and colleagues have demonstrated that C5a may
protectagainstexcitotoxicityandactivateneuroprotectivemitogen
activated protein kinase (108).
The data referring to the role of AMPs in AD are relatively
limited, although the inﬂammatory process occurring in AD is
associated with increased levels of HBD-1 mRNA in choroid
plexus epithelium and HBD-1 protein in hippocampal neurons
(109). Therefore, the nature of the AD inﬂammatory response is
complicated and involves both C system and AMPs.
COMPLEMENT AND AMPs IN MULTIPLE SCLEROSIS
CactivationinMSislesionandlocationdependent.Inwhitemat-
ter lesions, C3d and C4d are detected and most likely covalently
bound to myelin sheaths, while C3d, C1q, and C5 are associate
with disrupted myelin, micro- and astroglia, and vessel walls (15,
110, 111). It is possible that some C factors in the white matter
lesions are rapidly turned over as detection of C1q and MAC on
myelin sheaths so far has not been successful (15). In gray matter
lesions, C activation is very low (110), while in mixed white and
graymatterC3dandC4daredetectedonthemyelinsheathsonthe
borderof thelesionsandC3disonlyregisteredinthebloodvessels
(15).Theproductionof CfactorsinMSismostlikelyendogenous,
withmacrophagesconsideredasamainsourceof C1qandC3and
astroglia testing positive for C components in all lesions.
DirectlinkbetweenAMPsandMShasnotbeenyetestablished.
Ultraviolet-B irradiation and vitamin D are important factors
explaining the geographic variation and the increased prevalence
of MSinareaswithloweramountof sunshine(112).OnceMShas
developed,ultraviolet-B irradiation and vitamin D can reduce the
severity of the disease through vitamin D-induced apoptosis of
CD4 T lymphocytes (113). Vitamin D enhances innate immunity
and the transcription of cathelicidin (114) and different defensins
(115). Therefore, the balance of AMPs might be an important
factor associated with the control of the inﬂammatory process
in MS.
COMPLEMENT AND AMPs IN STROKE AND REPERFUSION INJURIES
The pathobiology of stroke involves an inﬂammatory response
associated with all stages of the ischemic cascade, starting from
theearlydamagingeventstriggeredbyarterialocclusiontothelate
regenerativeprocessesunderlyingpost-ischemictissuerepair(23).
Increased immunoreactivity for C1q, C3c, C4d, and C9, and vir-
tually absent C regulators were registered in ischemic lesions from
patients with acute brain ischemia or ischemic stroke, suggesting
activation of the classical C pathway (116). Therefore, the com-
bination of increased deposition of C components and decreased
expression of C regulators is a possible mechanism of tissue dam-
age during ischemia in human brain. Supporting evidence for this
hypothesisisprovidedbythestudyofVanBeekandcolleagueswho
characterized the expression of different C components following
permanent MCAO in the mouse (117). Their data demonstrate
increased levels of C1q and C4 mRNA in ischemic cortex and
increased expression of C4 in perifocal neurons suggesting local
expression of C components, which (i) may contribute to the
inﬂammatoryprocessandrepresentakeycomponentinsecondary
injuryand(ii)mayresultintheformationof MACandcontribute
to host cell lysis (117). The role of the AP in ischemic stroke has
not yet been fully investigated, although a study by Elvington and
colleaguesinamurinemodelof MCAOsuggeststhattheAPprop-
agates cerebral inﬂammation and injury through ampliﬁcation of
the complement cascade (118).
Conversely, some data suggest protective role of the C sys-
tem following ischemic injury, proposing that C activation does
not appear to be a primary contributor to brain injury in a
rabbit model of acute thromboembolic stroke (119) and also
that C activation contributes to remodeling during repair in the
CNS (73).
There is no data directly connecting AMP expression and
stroke, although the inﬂammatory response resulting from
ischemicinjurycanbeassociatedwithAMPproduction.Williams
and colleagues proposed that central to the innate and adap-
tive immune response, and the prolongation of inﬂammation
within the brain, is a dysregulation of constitutively expressed
and inducible AMPs (84). In vitro exposure of human primary
epithelial cells to high levels of glucose or low insulin results in
decreased expression of HBD-2 and HBD-3 (84). Ischemic events
in the adult brain are associated with the occurrence of chronic
hyperglycemia,whichcancontributetoglycationofspeciﬁcamino
acid residues on AMPs, resulting in conformational changes and
inhibition or prolongation of AMP function (84,120). Therefore,
the balance of AMP expression in the brain might be crucial for
the inﬂammatory processes and subsequent occurrence of brain
damage in the CNS.
COMPLEMENT AND NEONATAL HI
Complement is an essential aspect of innate immunity, and plays
arolenotonlyinnormalbrainphysiologybutalsoduringpathol-
ogy,includingischemia.Experimentalresearchusingrodentmod-
els of HI are now starting to clarify its role in hypoxic-ischemic
brain injury.
A hallmark of hypoxia-ischemia primary energy failure is aci-
dosis. A study by Sonntag and colleagues looking at umbilical
arterial pH 22–28h after birth has shown that serum C3a and C5a
are increased after fetal acidosis (121). Another clinical study has
demonstrated that circulating C3 is reduced following neonatal
asphyxia (122). Initial experimental rodent studies have shown
thatC9administrationappearedtobedetrimental(123),andthat
cobra venom factor (CVF) treatment did not affect HI induced
brain injury in a study by Lassiter et al. (124). However, this
same treatment approach was performed subsequently by Cow-
ell and colleagues, and shown that CVF pretreatment decreases
braininfarctionfollowingneonatalHI(125).Precisestudiesusing
C1q knockout mice were used to investigate the classical C path-
way role in neonatal HI. A study by Ten and colleagues revealed
that C1q /  mice had substantial reduction in brain infarction,
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as well as neurofunctional impairment when compared to wild
type controls. Furthermore, wild type mice demonstrated greater
deposits of C1q and C3 deposits within the brain as well as the
presenceof granulocytesintheareaof infarction(126).Thisstudy
strongly suggests that classical complement activation and subse-
quent brain deposition of C1q and C3 is not only associated with
inﬁltration of granulocytes but also with HI brain injury. This
hypothesis was further strengthened when the same group looked
atbrainmitochondria,anddemonstratedthatneuronsof C1q / 
mice were resistant to hypoxia-ischemia, with preserved brain
mitochondria respiration, and reduced production of reactive
oxygen species. Additionally, this study demonstrated that clas-
sical complement activation detrimental role in hypoxic-ischemic
injury does not involve activation of MAC (127).
C3 is expressed in the brain by both neurons and glial cells
(Table 3). Its activation and subsequent generation of C3a is
known to have pro-inﬂammatory properties, and its expression
appears to be detrimental in several models of CNS injury.
However, C3a also has anti-inﬂammatory properties following
LPS administration, by decreasing LPS-mediated cytokine release
(128). Additionally, in vitro studies have shown its neuropro-
tective effects by acting on both microglia (129) and astrocytes
(130). C3a can bind to its canonical receptor C3aR, and accord-
ing to some controversial data to the alternative receptor C5L2
(131–133), which is expressed in both neurons and glia cells
and has anti-inﬂammatory properties (134). However, in a study
by Järlestedt and colleagues, it was demonstrated that canonical
over-expression of C3a in astrocytes resulted in reduction of HI-
induction of hippocampal tissue loss, as well as reduced numbers
of astrocytes and microglia/macrophages in the ipsilateral stria-
tum,suggesting that C3a protective role following HI is a result of
its binding to C3aR (135).
Overall, experimental studies have shown that C1q is highly
present in the brain following ischemia (136), and that classical
complement pathway activation via C1q generates C3a and C5a
pro-inﬂammatory mediators, which are associated with HI brain
injury (137, 138), as well as complement-associated genes (16).
Additionally, deletion of C1q not only reduces brain infarction
and neurofunctional deﬁcit but also results in protection of mito-
chondria respiration, indicating a role for classical complement
activation and brain oxidative stress (127), and demonstrating a
link between innate immunity and oxidative stress. Conversely,
C3aR-mediated activation of C3a has also revealed a degree of
protection following HI insult.
AMPs AND NEONATAL HI
Currently,thereisnodirectevidencefortheinvolvementof AMPs
in neonatal HI brain damage. In respect of the capability of the
CNS to locally produce AMPs and the evidence for their partic-
ipation in inﬂammation-associated diseases such as AD and MS,
AMP involvement in neonatal HI inﬂammation and subsequent
brain damage is quite possible.
As previously described neonatal HI triggers an inﬂammatory
response including activation of microglia, astroglia, DC, and is
associated with release of pro- and anti-inﬂammatory cytokines,
chemokines, and adhesion molecules. According to Bain and col-
leagues one of the reasons for the occurrence of HI brain damage
is the misbalance in the release of pro- (IL-1, IL-6, IL-8, TNF-a)
and anti-inﬂammatory (IL-10) cytokines promoting differentia-
tion of oligodendrocyte precursor cells into astrocytes, but not
oligodendrogliathusimpairingsubsequentmyelination(139).Ina
mousemodelof neonatalHI,Shrivastavaandcolleaguesobserved
up-regulation of pro-inﬂammatory IL-1b, IL-6, and TNF-a and
modulation of anti-inﬂammatory cytokines IL-1 receptor antag-
onist, IL-4, IL-13, and IL-10 (140). The up-regulation of IL-1b is
to a great extent due to microglial activation in response to the
HIinjuryandsubsequentlyaffectsastrogliosis.BothIL-1andIL-6
have been implicated in the induction and modulation of reac-
tive astrogliosis (141). Microglial IL-1b might be directly affecting
astroglial activation (142), while the effects of IL-6 on astroglio-
sis might be either direct or through the JAK2/STAT3 pathway as
STAT3 is a critical transcription factor regulating astroglial mat-
uration and GFAP expression (143, 144). Activated astroglia can
subsequently produce HBD-2 (83) and alter the innate immune
response in the brain following neonatal HI injury.
Neonatal HI might be directly affecting astrocytes promot-
ing IL-1b (142) production, which can amplify astroglial and
microglial activation and stimulate both cell types to produce
AMPs. Conversely, activated astrocytes can also down regulate
microglial activation through production of anti-inﬂammatory
cytokinessuchastransforminggrowthfactorbandprostaglandin
E2 (145, 146) thus limiting inﬂammation and subsequent neu-
rodegeneration (142). This can potentially affect microglial pro-
duction of AMPs.
Post-HI hyperglycemia is harmful for the HIE (147).Although
results obtained from adult experiments cannot be directly trans-
ferredandusedasexplanationforneonataldataduetodifferences
inthelevelof maturationandenzymedevelopment(5,140),some
pathwaysmightbevalidinadultaswellasneonatalset-up.There-
fore,observations of lowAMP levels due to hyperglycemia and/or
increased insulin resistance associated with many neuropatholo-
gies such as AD (84) might be also valid following neonatal HI.
Reduction of mRNA for HBD-2 and HBD-3 has been observed
after in vitro exposure of human epithelial cells to high glu-
cose and/or low insulin (84). Therefore, the detrimental effects
of hyperglycemia following neonatal HI might be attributed to
alteration of AMP production.
Toll like receptors are important for antigen recognition in
the CNS. TLR-regulated responses can control elimination of cell
debris and promote repair in the brain (148) and are suggested to
play an important part in CNS inﬂammatory conditions, includ-
ingischemia(141,149).MicroglialcellsexpressTLRsandrespond
to TLR ligands (Figure1) (148). TLR-4 is expressed by astrocytes,
endothelial cells,and neurons (150,151). Hao and colleagues sug-
gested that astrocytic production of HBD-2 depends on cytokine
stimulation of TLR,IL-1b,and TNF-a receptors (83). The precise
mechanismthroughwhichastrocytesproducedefensinsisunclear,
but TLRs induce NF-kB activation in response to cytokines and
bacterialtoxins,thusstimulatingastrocytestoproduceAMPs(64)
(Figure 1). This hypothesis might be also valid in respect to
astrocytic AMP production following neonatal HI.
Another mechanism through which AMPs might be affecting
the inﬂammatory response following neonatal HI is through their
ability to recruit immature DC to the site of inﬂammation and
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promote DC maturation through TLR-4, thus modulating the
adaptive immune response of the brain (152).
All these suggest that misbalance of constitutively expressed
(HBD-1)andinducible(HBD-2,HBD-3)AMPs,aswellascatheli-
cidin(LL-37)islikelytooccurincasesof inﬂammation-associated
neurodegeneration in the adult brain, as well as following neona-
tal HI.
So far, there is no evidence suggesting direct damaging effects
of AMPs on mammalian cells (83). Supportive evidence for the
role of AMPs in the innate immune response following neonatal
HI is the use of novel innate defense regulator peptides (IDRs)
in animal models of neonatal cerebral inﬂammation and injury.
IDRsaresyntheticderivativesof endogenouscationichostdefense
peptidessuchascathelicidin,selectivelysuppressinginﬂammation
and augmenting protective immunity to pathogens (153–155).
Recently,BolouriandcolleaguesdemonstratedthatIDR-1018sup-
pressed pro-inﬂammatory gene regulation in a neonatal mouse
model of LPS-sensitized HI damage (156). The same group also
suggested that post-HI treatment with IDR-1018 reduces LPS-
induced HI brain damage. Therefore, IDRs might be promising
neuroprotective agents for neonatal HI.
CONCLUSION
Manyneurodegenerativedisordershavesimilarpathogenicmech-
anisms and data obtained from one disease may prove valid for
another. Thereis aconsiderable amountof informationin respect
to the role of the C system, but there is no direct evidence for the
involvement of AMPs in neonatal HI brain injury. Neonatal HI is
associated with a robust inﬂammatory response, involving rapid
change in neuronal gene expression associated with stimulation
and aggregation of astrocytes and microglia for survival support
(17). Activated microglia and astrocytes produce immunomodu-
latoryproteinssuchasCcomponents(73)andAMPs.Wepropose
that misbalance of those proteins affects the equilibrium between
pro- and anti-inﬂammatory cytokines in the CNS, resulting in
prolonged inﬂammatory response and subsequent brain injury
following neonatal HI. The regulation of the innate immune
response simultaneously with cellular repair in the CNS is very
complex, but the capability of both microglial and astroglial cells
to produce C components and AMPs under cytokine stimulation
suggestsaroleforbothtypesof proteinsinthebrain.Whetherthis
roleisassociatedwiththeinitiationorprolongationof theinﬂam-
matory response and subsequent damage following neonatal HI
is unclear and needs further investigation. Deletion of some com-
plement components such as C1q, as well as over-expression of
others (C3a) has proven protective in neonatal HI brain damage.
Application of CVF, C1-inhibitor, C3-inhibition through solu-
ble CR1 or C3-deletion, as well as immunoglobulin treatment,
have all shown protective effects in adult stroke animal models
(157), suggesting that complement-targeted therapy could prove
effective in neonatal HI and needs further investigation. The pro-
tective effects of IDRs in neonatal mouse models of HI suggest
a potential key role for AMPs in the inﬂammatory response fol-
lowing neonatal HI brain injury. In conclusion,both C andAMPs
appear to be key modulators of the innate and to some extent
adaptive immune response following neonatal HI, which makes
them potential candidates for neuroprotective strategy.
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